Invega (Paliperidone) is considered a newer spin-off of the antipsychotic Risperdal in that it contains the same active metabolite, but is thought to have fewer side effects and drug interactions. It was initially approved in 2006 for the treatment of schizophrenia and was since granted approval for the treatment of schizoaffective disorder in 2009. While …
Invega (Paliperidone) is an atypical antipsychotic approved in 2006 for the treatment of schizophrenia. Several years later in 2009, a longer-acting format of the medication called “Invega Sustenna” was also approved. Invega Sustenna is an injectable form of the drug that is administered every 4 weeks and is thought to be advantageous it mitigates risk …
Fanapt (Iloperidone) is an antipsychotic that was approved in 2009 for the treatment of schizophrenia. It functions similar to most current-market atypical antipsychotics in that it acts as an antagonist of the 5-HT2A receptor and D2 dopamine receptor. It is thought to produce fewer extrapyramidal side effects (e.g. akathisia) compared to other antipsychotics. The drug …
Fanapt (Iloperidone) is an atypical antipsychotic that was approved by the FDA on May 6, 2009 for the treatment of schizophrenia. The drug is thought to have been synthesized in the 1990s, during which its rights were sold from Hoechst Marion Roussel Inc. to Titan Pharmaceuticals, and eventually to Vanda Pharmaceuticals. It functions as an …
Saphris (Asenapine) is a drug that was approved by the FDA in 2007 for the treatment of schizophrenia and the manic phases of bipolar disorder. It functions by acting primarily on 5-HT2A serotonergic receptors and D2 dopaminergic receptors as an antagonist. It also elicits effects on a variety of other serotonergic receptors (5HT2B, 5HT2C, 5HT6, …
Saphris (Asenapine) is an atypical antipsychotic medication that was approved in 2009 for the treatment of schizophrenia and bipolar disorder. It is a relatively new atypical antipsychotic, and is considered a chemical derivative of the tetracyclic antidepressant (TeCA) mianserin. It is manufactured in a sublingual format, which some may perceive as an upgraded or novel …
It appears as though the pharmaceutical juggernaut Eli Lilly is facing major legal backlash for failure to disclose discontinuation effects associated with their medication Cymbalta (Duloxetine). Cymbalta is an SNRI antidepressant that was approved in August 2004 for the treatment of major depression. A woman named Claudia Herrera has been making news headlines because she …